Switching from subcutaneous to oral semaglutidein type 2 diabetes: A prospective study

Thumbnail Image

Files

Journal of Internal Medicine - 2023 - Mart nez‐Montoro - Switching from subcutaneous to oral semaglutide in type 2 diabetes.pdf (198.67 KB)

Identifiers

URI: https://hdl.handle.net/10630/28014
DOI: 10.1111/joim.13737

Publication date

2023-10-30

Reading date

Authors

Collaborators

Advisors

Tutors

Editors

Journal Title

Journal ISSN

Volume Title

Publisher

Wiley

Metrics

Google Scholar

Share

Export

Research Projects

Organizational Units

Journal Issue

Center

Department/Institute

IBIMA. Instituto de Investigación Biomédica de Málaga

Keywords

Diabetes
Diabetes tipo 2
Semaglutida

Abstract

Description

Bibliographic citation

Martínez-Montoro, JI, Picón-César, MJ, Generoso-Piñar, M, Fernández-Valero, A, López-Montalbán, Á, Simón-Frapolli, VJ, et al. Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study. J Intern Med. 2023; 00: 00–00.

Collections

Artículos

Endorsement

Review

Supplemented By

Referenced by

Creative Commons license

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwised noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional